# ATTEC

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/attec

- Industry: Biotechnology
- Headquarters: Hangzhou, China
- Latest round: Series A (Feb 2, 2026)
- Investors on record: 5

## About

Established in 2019 and based in Hangzhou, China, Shanghai Atech Biotechnology Co., Ltd., dba ATTEC is a protein degradation drug development company, committed to providing novel therapeutic solutions for untargeted disease-causing proteins or non-druggable targets. The company's founder, Professor Ding, is a professor in the School of Life Sciences at Fudan University and has published more than 40 SCI papers in prestigious international journals such as Nature and Cell Research. In February 2026, ATTEC raised Series A+ funding from returning investors Furong Capital, Shanghai Industrial Investment and new investors Casstar Capital, Ennovation Ventures.
The company focuses on autophagy-lysosome-targeted degradation of small molecule colloids and uses ATTEC technology to study protein degraders, established the ATTEC small molecule glue screening technology platform and licensed the technique of oblique incident light reflection difference method developed by Yiyan Fei, Associate Researcher of Fudan University.
The company generates revenue from providing protein degradation drug and novel therapeutic solutions.

## Funding rounds

- Series A, Feb 2, 2026 — Casstar Capital, Furong Capital, Ennovation Ventures, Shanghai Industrial Investment
- Series A, Jun 17, 2025 — Furong Capital, Shanghai Industrial Investment
- Angel, Dec 17, 2020 — Shulan Junjie Capital

## Investors

- Shulan Junjie Capital (https://capitalatlas.ai/funds/shulan-junjie-capital) — Angel
- Furong Capital (https://capitalatlas.ai/funds/furong-capital) — Series A
- Shanghai Industrial Investment (https://capitalatlas.ai/funds/shanghai-industrial-investment) — Series A
- Casstar Capital (https://capitalatlas.ai/funds/casstar-capital) — Series A
- Ennovation Ventures (https://capitalatlas.ai/funds/ennovation-ventures) — Series A